AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Prospera Financial Services Inc

Prospera Financial Services Inc lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 9.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 103,247 shares of the company's stock after acquiring an additional 9,080 shares during the period. Prospera Financial Services Inc's holdings in AstraZeneca were worth $8,044,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of AZN. McClarren Financial Advisors Inc. boosted its position in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock worth $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca in the second quarter valued at $26,000. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the third quarter valued at $28,000. Pathway Financial Advisers LLC acquired a new stake in AstraZeneca in the first quarter worth about $29,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after buying an additional 146 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Price Performance

Shares of AZN traded up $0.46 during mid-day trading on Tuesday, hitting $63.85. 3,171,357 shares of the company were exchanged, compared to its average volume of 5,282,964. The stock has a market cap of $197.97 billion, a price-to-earnings ratio of 30.33, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a 50 day moving average of $74.68 and a 200-day moving average of $78.15.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analysts' expectations of $13.08 billion. During the same period in the previous year, the company earned $0.87 earnings per share. AstraZeneca's quarterly revenue was up 18.0% compared to the same quarter last year. Analysts expect that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. TD Cowen lifted their target price on AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, AstraZeneca currently has a consensus rating of "Buy" and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.